NovaScan LLC
This article was originally published in Start Up
Executive Summary
The rates of reoperation after breast conservation therapy vary between 25 and 49%, due to the presence of tumor cells remaining in the surrounding tissue after the tumor is removed. NovaScan hopes to reduce the need for these reoperations. Its FastPath residual cancer probe is designed to identify normal, benign and malignant tissue types remaining inside the surgical cavity and in excised tissue in real time during surgery.
You may also be interested in...
Snapshot: August Highlights
A selection of articles you may have missed from August 2023, including a breakdown of CEO pay, a discussion on being out and proud in the life sciences sector, and some hopeful discourse on the investment landscape going into 2024.
Execs On The Move: August 2023
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Insitro’s Daphne Koller On The Marriage Of Biology And Machine Learning At The Company’s Heart
Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.